One To Watch

Avidity Biosciences

Company Overview

A San Diego-based biotechnology company that pioneered muscle-targeted RNA delivery through its proprietary Antibody Oligonucleotide Conjugate platform, Avidity Biosciences was acquired by Novartis in February 2026 for approximately $12 billion. Founded in 2013, Avidity built the first demonstrated system for delivering RNA therapeutics selectively to muscle tissue — a capability that had long eluded the RNA field. Its three clinical programs, all in rare muscle diseases, validated the platform across distinct genetic targets. Avidity is now a wholly-owned subsidiary of Novartis, having been delisted from the Nasdaq Global Select Market where it traded under the ticker RNA.

Headquarters and Global Presence

Avidity Biosciences is headquartered in San Diego, California. Prior to its acquisition, it operated as an independent US-listed biotech; it now sits within Novartis's neuroscience and rare disease infrastructure as a wholly-owned subsidiary.

Founding and History

Avidity was founded in 2013 with the explicit aim of solving RNA delivery to muscle — a problem that had blocked the oligonucleotide therapeutics field for years. Co-founder and Chief Scientific Officer Arthur A. Levin, PhD, provided the scientific foundation for the AOC platform. The company raised approximately $345.1 million in a public offering in August 2024 and closed an oversubscribed $400 million private placement in February 2024, financing its clinical programs through to late-stage readouts. Novartis announced the acquisition in late October 2025 and closed the deal on February 27, 2026, at $72.00 per share — a 46% premium to the pre-announcement price.

Therapy Areas and Focus

Avidity concentrated its clinical pipeline entirely on rare neuromuscular diseases, specifically myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). Each of these conditions lacks disease-modifying treatment, and each is driven by a discrete genetic mechanism — making them well-suited to RNA-based silencing or splicing correction. The unmet need is significant: DM1 is the most common adult-onset muscular dystrophy, while FSHD and DMD44 together represent tens of thousands of patients with no approved causal therapy. Avidity's bet was that precision muscle delivery, not just precision RNA chemistry, was the missing variable.

Technology Platforms and Modalities

The AOC platform conjugates a monoclonal antibody — which provides tissue-targeting specificity — directly to an oligonucleotide payload, enabling RNA delivery to muscle cells that bare oligonucleotides cannot efficiently reach. The antibody component binds a receptor expressed on muscle, facilitating cellular uptake, while the oligonucleotide executes the RNA intervention: silencing a pathogenic gene or correcting aberrant splicing depending on the program. Avidity was the first company to demonstrate this approach successfully in human muscle, a claim that underpins the platform's commercial and scientific value. The consistency of biomarker responses across three genetically distinct diseases in clinical trials is the clearest evidence the delivery mechanism works as a platform rather than as a one-off.

Key Pipeline and Programs

Del-brax (delpacibart braxlosiran, AOC 1020) is the most clinically advanced and commercially closest program. It is an AOC targeting DUX4 — the double homeobox 4 gene whose aberrant reactivation drives FSHD — with the intent of silencing the root-cause pathology rather than managing symptoms. Phase 1/2 FORTITUDE trial data showed greater than 50% reductions in DUX4-regulated genes, mean reductions of 25% or greater in a novel circulating biomarker and creatine kinase, and consistent improvement across functional and patient-reported outcome measures versus placebo. Biomarker reductions held at 12 months across two cohorts. An accelerated-approval BLA submission is planned for H2 2026, which would make del-brax the first therapy targeting the genetic cause of FSHD.

Del-desiran (delpacibart desiran, AOC 1001) targets DMPK, the gene whose toxic RNA expansion causes DM1. It is the most advanced program by development stage, currently in the Phase 3 HARBOR trial — the pivotal study that would underpin a full regulatory submission.

Del-zota (delpacibart zotadirsen, AOC 1044) is designed for the DMD44 subpopulation, using exon-skipping to restore partial dystrophin expression. Avidity launched a US Managed Access Program for del-zota, allowing eligible patients access ahead of approval — a signal of confidence in the program's profile.

Recent Developments

The defining event was the close of Novartis's acquisition on February 27, 2026, at $72.00 per share — approximately $12 billion in total equity value, a 46% premium — making Avidity a Novartis subsidiary and removing it from public markets. Before closing, Avidity spun out its precision cardiology programs into a separate, independent publicly traded company (SpinCo), which Novartis did not acquire. Positive topline Phase 1/2 FORTITUDE data for del-brax in FSHD supported a planned H2 2026 accelerated-approval BLA filing, the clinical catalyst that made the deal attractive. The combination of a Phase 3 asset in DM1, a near-BLA asset in FSHD, and a managed-access program in DMD44 gave Novartis a fully staged rare neuromuscular franchise on a single delivery platform.

Key Personnel

Sarah Boyce serves as President and Chief Executive Officer of Avidity Biosciences. Arthur A. Levin, PhD, is co-founder and Chief Scientific Officer, the scientific architect of the AOC platform and its muscle-delivery thesis.

Strategic Partnerships

The acquisition by Novartis — announced in late October 2025 and closed February 27, 2026 — is the definitive strategic transaction, valued at approximately $12 billion and structured as an all-cash deal. Novartis acquired the muscle and neuromuscular AOC business in its entirety; the cardiology programs were separated into SpinCo prior to close and remain independent. No third-party licensing or co-development partnerships were disclosed in the research context beyond the Novartis transaction.

FAQ Section

Novartis was acquiring not just a pipeline but a validated delivery platform. Avidity had produced consistent clinical proof-of-concept across three genetically distinct rare muscle diseases using the same AOC technology — something no other company had done. With del-desiran in Phase 3 for DM1, del-brax heading toward an accelerated-approval BLA for FSHD, and del-zota in a managed access program for DMD44, Novartis was buying a fully staged rare neuromuscular franchise that would be difficult and slow to replicate internally.

Oligonucleotide therapies have long struggled to reach muscle efficiently because bare RNA molecules are rapidly cleared, don't cross cell membranes easily, and lack tissue selectivity. Avidity's solution was to conjugate the oligonucleotide directly to a monoclonal antibody that binds a receptor expressed on muscle cells, hijacking the cell's own uptake machinery to deliver the RNA payload. Being the first company to demonstrate this in human muscle — and then replicating the effect across three independent programs — is the platform's core claim to differentiation.

Del-brax is the first investigational therapy designed to target DUX4 directly — the gene whose aberrant reactivation is the accepted root cause of FSHD. No approved therapy currently addresses this mechanism; existing management is supportive. Phase 1/2 FORTITUDE data showed greater than 50% reductions in DUX4-regulated genes and durable biomarker reductions at 12 months, alongside functional and patient-reported improvements versus placebo, making it the most advanced disease-modifying candidate in FSHD and the asset closest to a regulatory submission.

Del-brax remains investigational, evaluated in the Phase 1/2 FORTITUDE trial. Avidity initiated a biomarker cohort within FORTITUDE specifically to support an accelerated-approval pathway, using significant reductions in DUX4-regulated genes and the novel circulating biomarker as surrogate endpoints. An accelerated-approval BLA submission is planned for H2 2026; if accepted, this would represent the first regulatory filing for an FSHD therapy targeting the genetic cause of the disease, now advanced within Novartis.

All three of Avidity's clinical programs target rare neuromuscular diseases: DM1, FSHD, and DMD44. Additional DMD subpopulations and rare neuromuscular programs were in earlier development. The cardiology programs — separated into SpinCo before the Novartis close — were built on precision RNA approaches but are now in an independent entity and outside Novartis's acquisition. Within Novartis, the AOC platform's further expansion will depend on the acquirer's strategic priorities for the muscle-delivery technology.

Del-desiran for DM1 is the most advanced, in the Phase 3 HARBOR trial. Del-brax for FSHD is Phase 1/2 complete with a BLA filing planned for H2 2026 under accelerated approval. Del-zota for DMD44 has a US Managed Access Program running ahead of approval. The acquisition closed February 27, 2026, and Avidity is now a Novartis subsidiary; pipeline advancement will continue under Novartis's rare disease and neuroscience infrastructure.

Avidity is now a Novartis subsidiary, but several material inflection points remain for the pipeline it brought in:

H2 2026 BLA submission for del-brax under accelerated approval — the FDA's willingness to accept DUX4-pathway biomarkers as surrogate endpoints is the pivotal regulatory question.
Phase 3 HARBOR readout for del-desiran in DM1 — the first pivotal efficacy test for the AOC platform and the program that could define the franchise's full commercial value.
Del-zota managed access data and eventual approval timeline in DMD44 — the smallest patient subpopulation but a disease with high unmet need and an established regulatory template for exon-skipping therapies.
Integration risk within Novartis — large-company absorption of a platform-stage biotech carries execution risk, particularly for programs still dependent on the original team's scientific expertise.
SpinCo's independent trajectory — the spun-out cardiology programs carry the AOC platform into a new tissue class; their progress will be watched as a read-across on platform breadth.

Want to Update your Company's Profile?